The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Merck’s efinopegdutide clears main goal in 386-patient phase 2b trial

Nov 10, 2026 01:25 (3h ago)

Verifying

Merck & Co. reported that efinopegdutide cleared the main goal of a phase 2b trial.
The MK-6024-013 study included 386 patients.
Efinopegdutide is being developed for the emerging MASH market.